• Kodiak Sciences Inc. recently reported fourth-quarter and full-year 2025 results showing wider net losses of US$56.74 million for the quarter and US$229.97 million for the year, alongside higher losses per share, while also filing a US$83.15 million shelf registration for 2,470,338 shares related to its ESOP.
• On the same day, auditor PricewaterhouseCoopers LLP issued an unqualified opinion but raised doubt about Kodiak Sciences’ ability to continue as a going concern, putting the company’s funding and business outlook under closer investor scrutiny.
• We’ll now examine how the auditor’s going concern warning shapes Kodiak Sciences’ investment narrative in light of its recent financial results.

Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is Kodiak Sciences' Investment Narrative?

For Kodiak Sciences, the core belief behind owning the stock is that its late‑stage eye disease pipeline, led by Zenkuda and KSI‑101, can eventually translate today’s heavy cash burn into future commercial value. The recent GLOW2 Phase 3 success and plans to accelerate a BLA submission keep the regulatory catalyst story intact in the near term, and the sharp share price move suggests the market is still focused on that upside. What has changed materially is the risk side of the equation: PwC’s renewed going concern warning, widening annual net losses of US$229.97 million, and the fresh US$83.15 million shelf tied to the ESOP all push funding, dilution and balance sheet resilience to the forefront of the narrative.

However, the auditor’s going concern flag is a risk investors should understand in detail. Kodiak Sciences' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Fair value estimates from the Simply Wall St Community span roughly US$33.69 to US$336.92 across 2 views, highlighting how far apart individual expectations can be. When you set that against Kodiak’s going concern warning and high cash burn, it underlines why some shareholders are focusing more on funding risk than on clinical milestones. This wide spread of opinion invites you to weigh multiple perspectives before forming your own view on the stock.

Explore 2 other fair value estimates on Kodiak Sciences - why the stock might be worth 22% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Kodiak Sciences research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.
• Our free Kodiak Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kodiak Sciences' overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 58 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 21 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.